140 related articles for article (PubMed ID: 15024187)
1. Effect of recombinant human keratinocyte growth factor (rHuKGF) on the immunopathogenesis of intestinal graft-vs.-host disease induced without a preconditioning regimen.
Ellison CA; Natuik SA; Fischer JM; McIntosh AR; Scully SA; Bow EJ; Danilenko DM; Hayglass KT; Gartner JG
J Clin Immunol; 2004 Mar; 24(2):197-211. PubMed ID: 15024187
[TBL] [Abstract][Full Text] [Related]
2. The role of interferon-gamma, nitric oxide and lipopolysaccharide in intestinal graft-versus-host disease developing in F1-hybrid mice.
Ellison CA; Natuik SA; McIntosh AR; Scully SA; Danilenko DM; Gartner JG
Immunology; 2003 Jul; 109(3):440-9. PubMed ID: 12807491
[TBL] [Abstract][Full Text] [Related]
3. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease.
Krijanovski OI; Hill GR; Cooke KR; Teshima T; Crawford JM; Brinson YS; Ferrara JL
Blood; 1999 Jul; 94(2):825-31. PubMed ID: 10397751
[TBL] [Abstract][Full Text] [Related]
4. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury.
Panoskaltsis-Mortari A; Taylor PA; Rubin JS; Uren A; Welniak LA; Murphy WJ; Farrell CL; Lacey DL; Blazar BR
Blood; 2000 Dec; 96(13):4350-6. PubMed ID: 11110712
[TBL] [Abstract][Full Text] [Related]
5. Effect of palifermin in a murine model of graft-versus-host disease (GVHD) associated with Th2 cytokine production, autoantibody production, and glomerulonephritis.
Ellison CA; Gibson IW; Hayglass KT; Gartner JG
J Clin Immunol; 2006 Sep; 26(5):485-94. PubMed ID: 16952010
[TBL] [Abstract][Full Text] [Related]
6. Graft-versus-host disease in recipients of grafts from natural killer T cell-deficient (Jalpha281(-/-)) donors.
Ellison CA; Taniguchi M; Fischer JM; Hayglass KT; Gartner JG
Immunology; 2006 Nov; 119(3):338-47. PubMed ID: 16879624
[TBL] [Abstract][Full Text] [Related]
7. Surfactant protein A is a required mediator of keratinocyte growth factor after experimental marrow transplantation.
Haddad IY; Milla C; Yang S; Panoskaltsis-Mortari A; Hawgood S; Lacey DL; Blazar BR
Am J Physiol Lung Cell Mol Physiol; 2003 Sep; 285(3):L602-10. PubMed ID: 12740217
[TBL] [Abstract][Full Text] [Related]
8. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease.
Rossi S; Blazar BR; Farrell CL; Danilenko DM; Lacey DL; Weinberg KI; Krenger W; Holländer GA
Blood; 2002 Jul; 100(2):682-91. PubMed ID: 12091365
[TBL] [Abstract][Full Text] [Related]
9. GVHD-associated enteropathy and endotoxemia in F1-hybrid recipients of NK1.1-depleted grafts.
Ellison CA; Amadeo RJ; Gartner JG
Scand J Immunol; 2001 Oct; 54(4):375-82. PubMed ID: 11555404
[TBL] [Abstract][Full Text] [Related]
10. Total parenteral nutrition-induced apoptosis in mouse intestinal epithelium: modulation by keratinocyte growth factor.
Wildhaber BE; Yang H; Teitelbaum DH
J Surg Res; 2003 Jun; 112(2):144-51. PubMed ID: 12888331
[TBL] [Abstract][Full Text] [Related]
11. Palifermin mediates immunoregulatory effects in addition to its cytoprotective effects in mice with acute graft-versus-host disease.
Ellison CA; Makar BM; Wiseman JM; Gheorghiu I; Taniguchi M; Gartner JG
J Clin Immunol; 2008 Sep; 28(5):600-15. PubMed ID: 18592360
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory effects of palifermin (recombinant human keratinocyte growth factor) in an SLE-like model of chronic graft-versus-host disease.
Ellison CA; Lissitsyn YV; Gheorghiu I; Gartner JG
Scand J Immunol; 2012 Jan; 75(1):69-76. PubMed ID: 21916922
[TBL] [Abstract][Full Text] [Related]
13. [Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation].
Zhao J; Zhao XY; Huang XJ
Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2497-502. PubMed ID: 16321278
[TBL] [Abstract][Full Text] [Related]
14. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
[TBL] [Abstract][Full Text] [Related]
15. Effect of keratinocyte growth factor on the proliferation, clonogenic capacity and colony size of human epithelial tumour cells in vitro.
Hille A; Rave-Fränk M; Pradier O; Damm C; Dörr W; Jäckel MC; Christiansen H; Hess CF; Schmidberger H
Int J Radiat Biol; 2003 Feb; 79(2):119-28. PubMed ID: 12569015
[TBL] [Abstract][Full Text] [Related]
16. Differential cytokine expression in acute and chronic murine graft-versus-host-disease.
Allen RD; Staley TA; Sidman CL
Eur J Immunol; 1993 Feb; 23(2):333-7. PubMed ID: 8436168
[TBL] [Abstract][Full Text] [Related]
17. Murine graft-versus-host disease in an F1-hybrid model using IFN-gamma gene knockout donors.
Ellison CA; Fischer JM; HayGlass KT; Gartner JG
J Immunol; 1998 Jul; 161(2):631-40. PubMed ID: 9670937
[TBL] [Abstract][Full Text] [Related]
18. AhR‑E2F1‑KGFR signaling is involved in KGF‑induced intestinal epithelial cell proliferation.
Yang K; Yin J; Sheng B; Wang Q; Han B; Pu A; Yu M; Sun L; Xiao W; Yang H
Mol Med Rep; 2017 May; 15(5):3019-3026. PubMed ID: 28339052
[TBL] [Abstract][Full Text] [Related]
19. Roquinimex-mediated protection effect on the development of chronic graft-versus-host disease in mice is associated with induction of Th1 cytokine production and inhibition of proinflammatory cytokine production.
Xiao ZY; Zhou WX; Zhang YX; Cheng JP; He JF; Yang RF; Yun LH
Life Sci; 2007 Oct; 81(19-20):1403-10. PubMed ID: 17950363
[TBL] [Abstract][Full Text] [Related]
20. Systemic Treatment with a miR-146a Mimic Suppresses Endotoxin Sensitivity and Partially Protects Mice from the Progression of Acute Graft-versus-Host Disease.
Gartner JG; Durston MM; Booth SA; Ellison CA
Scand J Immunol; 2017 Nov; 86(5):368-376. PubMed ID: 28853768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
